Veracyte announces expanded availability of Decipher prostate test to patients with metastatic prostate cancer

April 30, 2025

Veracyte, Inc. announced the launch of its Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has spread beyond the primary tumor.

The Decipher Prostate test, already widely used for patients with localized disease, is now the only gene expression test available and covered by Medicare to inform treatment decisions for patients across the full continuum of prostate cancer risk.  

Veracyte has begun making the Decipher Prostate Metastatic test available to select clinical sites through an early access program and will begin taking orders for the test more broadly in June 2025. 

Veracyte release

ID 177400875 © Elmer Grubbs | Dreamstime.com
dreamstime_xxl_177400875
ID 90790743 © Rido | Dreamstime.com
dreamstime_xxl_90790743_1
By Rawpixel.com on Adobe Stock
adobestock_137153252
By Jesse B/peopleimages.com on Adobe Stock
adobestock_557096555